相关临床试验
6
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1945
已完成
2
33.3%
尚未招募
1
16.7%
终止
1
16.7%
Unknown
2
33.3%
暂无批准数据
- Three Chugai scientists who led the creation of Hemlibra (emicizumab) for hemophilia A have received the Lasker-DeBakey Clinical Medical Research Award, one of the world's most prestigious scientific honors. - The award recognizes the unconventional concept of replacing coagulation Factor VIII's function with a bispecific antibody, enabling subcutaneous administration and sustained bleed prevention regardless of inhibitor status. - An integrated analysis of phase III HAVEN 1–4 studies showed an annualized bleeding rate of 1.4 events per year, with 82.4% of participants experiencing zero treated bleeds by Weeks 121–144. - Hemlibra is now approved in more than 120 countries and has been used by over 30,000 people with hemophilia A worldwide as of June 30, 2026.
- Japan will begin the world's first clinical trials for artificial blood by March 2025, led by Nara Medical University, marking a potential breakthrough in emergency medicine. - The artificial blood uses hemoglobin vesicles from expired donations encased in protective shells, eliminating blood type compatibility requirements and offering a two-year shelf life. - The technology addresses Japan's critical blood shortage crisis driven by an aging population and declining birth rates, with potential global applications. - If successful, the artificial blood could enter clinical use by 2030, providing a universal blood substitute for emergency situations and remote areas.
